0001640455-21-000012.txt : 20210120 0001640455-21-000012.hdr.sgml : 20210120 20210120203802 ACCESSION NUMBER: 0001640455-21-000012 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20210115 FILED AS OF DATE: 20210120 DATE AS OF CHANGE: 20210120 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: MURRAY RICHARD /CA/ CENTRAL INDEX KEY: 0001242935 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-37998 FILM NUMBER: 21540166 MAIL ADDRESS: STREET 1: 22643 WOODRIDGE CT CITY: CUPERTINO STATE: CA ZIP: 95014 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Jounce Therapeutics, Inc. CENTRAL INDEX KEY: 0001640455 STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836] IRS NUMBER: 454870634 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 BUSINESS PHONE: 857-259-3840 MAIL ADDRESS: STREET 1: 780 MEMORIAL DRIVE CITY: CAMBRIDGE STATE: MA ZIP: 02139 4 1 wf-form4_161119305278202.xml FORM 4 X0306 4 2021-01-15 0 0001640455 Jounce Therapeutics, Inc. JNCE 0001242935 MURRAY RICHARD /CA/ C/O JOUNCE THERAPEUTICS, INC. 780 MEMORIAL DRIVE CAMBRIDGE MA 02139 1 1 0 0 CEO and President Common Stock 2021-01-15 4 M 0 30000 0.48 A 170371 D Common Stock 2021-01-15 4 S 0 30000 8.54 D 140371 D Common Stock 2021-01-19 4 M 0 40000 0.48 A 180371 D Common Stock 2021-01-19 4 S 0 40000 9.59 D 140371 D Common Stock 2021-01-20 4 M 0 16482 0.48 A 156853 D Common Stock 2021-01-20 4 S 0 16482 12.04 D 140371 D Stock Option (Right to Buy) 0.48 2021-01-15 4 M 0 30000 0 D 2024-06-26 Common Stock 30000.0 755169 D Stock Option (Right to Buy) 0.48 2021-01-19 4 M 0 40000 0 D 2024-06-26 Common Stock 40000.0 715169 D Stock Option (Right to Buy) 0.48 2021-01-20 4 M 0 16482 0 D 2024-06-26 Common Stock 16482.0 698687 D The transactions reported on this Form 4 were effected pursuant to a 10b5-1 trading plan adopted by the Reporting Person on November 21, 2019 and modified on December 9, 2020. The Reporting Person exercised no discretion with respect to these transactions. Represents the weighted average share price of an aggregate total of 30,000 shares sold in the price range of $8.50 to $8.61 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 40,000 shares sold in the price range of $9.50 to $9.74 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. Represents the weighted average share price of an aggregate total of 16,482 shares sold in the price range of $12.00 to $12.11 by the Reporting Person. The Reporting Person undertakes to provide upon request by the Commission Staff, the issuer or a security holder of the issuer, full information regarding the number of shares sold at each separate price. 25% of the option shares vested and became exercisable on July 14, 2015 and the remainder of the option shares vest and become exercisable in 36 monthly installments thereafter. /s/ Kim C. Drapkin, Attorney-in-Fact 2021-01-20